Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PnuBioVax in Healthy Adults
NCT02572635Phase 1Completed
- Sponsor
- ImmunoBiology Limited
- Start
- Oct 2015
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pnubiovax in pneumococcal infection (4 arms), sponsored by ImmunoBiology Limited. Primary endpoint: Incidence of all treatment emergent adverse events. Started Oct 2015; status: completed.
02
Drugs
pnubiovax
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02572635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572635.